Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma

Gordon W. Dewald, Terry M Therneau, Dirk Larson, Kyoung Lee You, Stephanie Fink, Stephanie Smoley, Sarah Paternoster, Adewale Adeyinka, Rhett Ketterling, Daniel L. Van Dyke, Rafael Fonseca, Robert Kyle

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

The clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas interphase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17)(p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50% abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17)(p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.

Original languageEnglish (US)
Pages (from-to)3553-3558
Number of pages6
JournalBlood
Volume106
Issue number10
DOIs
StatePublished - Nov 15 2005

Fingerprint

Interphase
Metaphase
Chromosomes
Fluorescence
Fluorescence In Situ Hybridization
Survival
Chromosomes, Human, Pair 13
DNA Probes
Cytogenetics
Multiple Myeloma
Monosomy
Plasma Cells
Plasmas

ASJC Scopus subject areas

  • Hematology

Cite this

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. / Dewald, Gordon W.; Therneau, Terry M; Larson, Dirk; You, Kyoung Lee; Fink, Stephanie; Smoley, Stephanie; Paternoster, Sarah; Adeyinka, Adewale; Ketterling, Rhett; Van Dyke, Daniel L.; Fonseca, Rafael; Kyle, Robert.

In: Blood, Vol. 106, No. 10, 15.11.2005, p. 3553-3558.

Research output: Contribution to journalArticle

Dewald, GW, Therneau, TM, Larson, D, You, KL, Fink, S, Smoley, S, Paternoster, S, Adeyinka, A, Ketterling, R, Van Dyke, DL, Fonseca, R & Kyle, R 2005, 'Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma', Blood, vol. 106, no. 10, pp. 3553-3558. https://doi.org/10.1182/blood-2005-05-1981
Dewald, Gordon W. ; Therneau, Terry M ; Larson, Dirk ; You, Kyoung Lee ; Fink, Stephanie ; Smoley, Stephanie ; Paternoster, Sarah ; Adeyinka, Adewale ; Ketterling, Rhett ; Van Dyke, Daniel L. ; Fonseca, Rafael ; Kyle, Robert. / Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. In: Blood. 2005 ; Vol. 106, No. 10. pp. 3553-3558.
@article{b0487dcd7c564901b3470f663c4856cc,
title = "Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma",
abstract = "The clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas interphase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17)(p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40{\%}) patients. Abnormal interphase nuclei were observed in 133 (86{\%}) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50{\%} abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17)(p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.",
author = "Dewald, {Gordon W.} and Therneau, {Terry M} and Dirk Larson and You, {Kyoung Lee} and Stephanie Fink and Stephanie Smoley and Sarah Paternoster and Adewale Adeyinka and Rhett Ketterling and {Van Dyke}, {Daniel L.} and Rafael Fonseca and Robert Kyle",
year = "2005",
month = "11",
day = "15",
doi = "10.1182/blood-2005-05-1981",
language = "English (US)",
volume = "106",
pages = "3553--3558",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "10",

}

TY - JOUR

T1 - Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma

AU - Dewald, Gordon W.

AU - Therneau, Terry M

AU - Larson, Dirk

AU - You, Kyoung Lee

AU - Fink, Stephanie

AU - Smoley, Stephanie

AU - Paternoster, Sarah

AU - Adeyinka, Adewale

AU - Ketterling, Rhett

AU - Van Dyke, Daniel L.

AU - Fonseca, Rafael

AU - Kyle, Robert

PY - 2005/11/15

Y1 - 2005/11/15

N2 - The clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas interphase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17)(p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50% abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17)(p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.

AB - The clinical efficacy of evaluating genetic anomalies in metaphase cells versus interphase nuclei for multiple myeloma (MM) is poorly understood. Therefore, survival for 154 patients with newly diagnosed untreated MM was compared with results from analysis of metaphase and interphase cells. Metaphases were studied by conventional cytogenetics and fluorescent-labeled DNA probes (fluorescence in situ hybridization [FISH]), whereas interphase nuclei were evaluated only by FISH. All FISH studies were done using DNA probes to detect t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23), del(17)(p13.1), and chromosome 13 anomalies. Metaphases were abnormal by cytogenetics and/or metaphase FISH in 61 (40%) patients. Abnormal interphase nuclei were observed in 133 (86%) patients, including each patient with abnormal metaphases. FISH was a necessary adjunct to cytogenetics to detect t(4;14) and t(14;16) in metaphase cells. Patient survival was especially poor for patients with greater than 50% abnormal interphase nuclei, although this result was more likely due to level of plasma cells than specific chromosome anomalies. For metaphase data, patients with t(4;14), t(14;16), del(17)(p13.1), and/or chromosome 13 anomalies (primarily monosomy 13) had poor survival. A different outcome was observed for interphase data as patients with t(4;14) or t(14;16) had poor survival, whereas patients with chromosome 13 anomalies had intermediate survival: interphase FISH did not substitute for metaphase analysis.

UR - http://www.scopus.com/inward/record.url?scp=27744568383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27744568383&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-05-1981

DO - 10.1182/blood-2005-05-1981

M3 - Article

C2 - 16030187

AN - SCOPUS:27744568383

VL - 106

SP - 3553

EP - 3558

JO - Blood

JF - Blood

SN - 0006-4971

IS - 10

ER -